Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-11-07
DOI
10.3389/fonc.2019.01186
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy
- (2019) Naveen Pemmaraju et al. BLOOD
- The Role of New Technologies in Myeloproliferative Neoplasms
- (2019) Giuseppe A. Palumbo et al. Frontiers in Oncology
- Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
- (2018) Martin Griesshammer et al. ANNALS OF HEMATOLOGY
- Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
- (2018) Edit Porpaczy et al. BLOOD
- Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
- (2018) Nicola Polverelli et al. HEMATOLOGICAL ONCOLOGY
- Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages
- (2018) Marie Febvre-James et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
- (2018) Hans Michael Kvasnicka et al. Journal of Hematology & Oncology
- The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium
- (2017) Martin Griesshammer et al. EXPERT OPINION ON PHARMACOTHERAPY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
- (2017) Palma Manduzio Therapeutics and Clinical Risk Management
- Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency
- (2016) A. P. A. Theocharides et al. BLOOD
- Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
- (2016) Jeffrey C. Bryan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK
- (2016) J Rudolph et al. LEUKEMIA
- Novel targets in the treatment of chronic graft-versus-host disease
- (2016) A Im et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Topical Ruxolitinib for the Treatment of Alopecia Universalis
- (2016) Brittany G. Craiglow et al. JAMA Dermatology
- Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade
- (2016) Shane A. Curran et al. Cancer Immunology Research
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms
- (2015) Sowmya Parampalli Yajnanarayana et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells
- (2015) Clodagh Keohane et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
- (2015) Kathrin Schönberg et al. CANCER RESEARCH
- American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
- (2015) Robert P. Perrillo et al. GASTROENTEROLOGY
- JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
- (2015) C. Harrison HAEMATOLOGICA
- Leukemic Diffuse Large B-Cell Lymphoma in a Patient With Myeloproliferative Disorder
- (2015) Vijaya Raj Bhatt et al. Journal of the National Comprehensive Cancer Network
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
- (2015) R Zeiser et al. LEUKEMIA
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transient blocking of NK cell function with small molecule inhibitors for helper dependant adenoviral vector-mediated gene delivery
- (2015) Manjunatha Ankathatti Munegowda et al. Cell and Bioscience
- Immunological Consequences of JAK Inhibition: Friend or Foe?
- (2015) Donal P. McLornan et al. Current Hematologic Malignancy Reports
- JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
- (2015) C. Harrison HAEMATOLOGICA
- Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge
- (2014) Francesca Palandri et al. ANNALS OF HEMATOLOGY
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
- (2014) S. Spoerl et al. BLOOD
- Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage
- (2014) Lukas Schwab et al. NATURE MEDICINE
- Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
- (2014) Jaebok Choi et al. PLoS One
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
- (2013) Nicholas G. Wysham et al. CHEST
- Jakpot! New small molecules in autoimmune and inflammatory diseases
- (2013) Kamran Ghoreschi et al. EXPERIMENTAL DERMATOLOGY
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
- (2013) S. Verstovsek et al. HAEMATOLOGICA
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
- (2013) M Massa et al. LEUKEMIA
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib
- (2013) Roger A. Goldberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of JAKs in Macrophages Increases Lipopolysaccharide-Induced Cytokine Production by Blocking IL-10-Mediated Feedback
- (2012) M. J. Pattison et al. JOURNAL OF IMMUNOLOGY
- Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
- (2012) Naresh Punwani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
- (2011) Alfonso Quintás-Cardama et al. NATURE REVIEWS DRUG DISCOVERY
- SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage
- (2010) M. Giroux et al. BLOOD
- Regulatory T cells exert checks and balances on self tolerance and autoimmunity
- (2009) Kajsa Wing et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search